AYALA PHARMACEUTICALS INC (AYLA) Stock Price, Quote, News and Overview
NASDAQ:AYLA - Nasdaq - US05465V1089 - Common Stock - Currency: USD
AYLA Quote, Performance and Key Statistics
NASDAQ:AYLA (1/18/2023, 8:00:01 PM)
0.5036
+0.03 (+5.84%)
The current stock price of AYLA is 0.5036 USD. In the past month the price increased by 0.68%. In the past year, price decreased by -92.53%.
AYLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.48 | 335.32B | ||
| AMGN | AMGEN INC | 13.99 | 156.11B | ||
| GILD | GILEAD SCIENCES INC | 14.53 | 139.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.23B | ||
| ARGX | ARGENX SE - ADR | 101.9 | 35.78B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.54 | 27.66B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| NTRA | NATERA INC | N/A | 22.36B | ||
| BIIB | BIOGEN INC | 8.42 | 19.51B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.29B |
Related stock screener links
About AYLA
Company Profile
Ayala Pharmaceuticals, Inc. operates as a clinical-stage oncology company. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-05-08. The firm's portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors (GSIs). AL101 and AL102 are designed to address the underlying key drivers of tumor growth. The firm is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC), for patients bearing Notch-activating mutations. The firm also developing AL102 for the treatment of other rare indications including T-ALL, an aggressive, rare form of T-cell specific leukemia. The firm is also conducting its ongoing Phase II ACCURACY trial for the treatment of R/M ACC in subjects with progressive disease and Notch-activating mutations.
Company Info
AYALA PHARMACEUTICALS INC
1313 N. Market Street, Suite 5100
Wilmington DELAWARE 7670104 US
CEO: Roni Mamluk
Employees: 35
Phone: 18574440553.0
AYALA PHARMACEUTICALS INC / AYLA FAQ
What is the stock price of AYALA PHARMACEUTICALS INC today?
The current stock price of AYLA is 0.5036 USD. The price increased by 5.84% in the last trading session.
What is the ticker symbol for AYALA PHARMACEUTICALS INC stock?
The exchange symbol of AYALA PHARMACEUTICALS INC is AYLA and it is listed on the Nasdaq exchange.
On which exchange is AYLA stock listed?
AYLA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AYALA PHARMACEUTICALS INC stock?
9 analysts have analysed AYLA and the average price target is 12.24 USD. This implies a price increase of 2330.5% is expected in the next year compared to the current price of 0.5036. Check the AYALA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AYALA PHARMACEUTICALS INC worth?
AYALA PHARMACEUTICALS INC (AYLA) has a market capitalization of 7.46M USD. This makes AYLA a Nano Cap stock.
How many employees does AYALA PHARMACEUTICALS INC have?
AYALA PHARMACEUTICALS INC (AYLA) currently has 35 employees.
What are the support and resistance levels for AYALA PHARMACEUTICALS INC (AYLA) stock?
AYALA PHARMACEUTICALS INC (AYLA) has a support level at 0.47 and a resistance level at 0.53. Check the full technical report for a detailed analysis of AYLA support and resistance levels.
Is AYALA PHARMACEUTICALS INC (AYLA) expected to grow?
The Revenue of AYALA PHARMACEUTICALS INC (AYLA) is expected to decline by -33.92% in the next year. Check the estimates tab for more information on the AYLA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AYALA PHARMACEUTICALS INC (AYLA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AYLA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AYLA, evaluating the profitability, health, valuation and growth aspects
- AYALA PHARMACEUTICALS INC (AYLA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AYALA PHARMACEUTICALS INC (AYLA) Sales and EPS estimates to see what analysts future expectations are.
- AYALA PHARMACEUTICALS INC (AYLA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AYALA PHARMACEUTICALS INC (AYLA) Insider and Institutional Ownership to learn about the owners and their transactions.
- AYALA PHARMACEUTICALS INC (AYLA) Stock Chart to make your own analysis
- AYALA PHARMACEUTICALS INC (AYLA) Latest news and press-releases to stay up to date.
Does AYALA PHARMACEUTICALS INC (AYLA) stock pay dividends?
AYLA does not pay a dividend.
When does AYALA PHARMACEUTICALS INC (AYLA) report earnings?
AYALA PHARMACEUTICALS INC (AYLA) will report earnings on 2023-03-27.
What is the Price/Earnings (PE) ratio of AYALA PHARMACEUTICALS INC (AYLA)?
AYALA PHARMACEUTICALS INC (AYLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.52).
AYLA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to AYLA. When comparing the yearly performance of all stocks, AYLA is a bad performer in the overall market: 96.41% of all stocks are doing better.
AYLA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AYLA. Both the profitability and financial health of AYLA have multiple concerns.
AYLA Financial Highlights
Over the last trailing twelve months AYLA reported a non-GAAP Earnings per Share(EPS) of -2.52. The EPS increased by 13.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AYLA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to AYLA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 3.59% and a revenue growth -33.92% for AYLA